Eslicarbazepine acetate response in intellectual disability population versus general population.

Tittensor, Phil

Eslicarbazepine acetate response in intellectual disability population versus general population.

Authors

Tittensor, Phil

Issue Date

2021-03-01

Type

Retrospective Study
Peer-Reviewed Publication

Keywords

Eslicarbazepine acetate
Intellectual disability
Epilepsy
Epilepsy
UK-based Epilepsy Database Research Register (Ep-ID)
Seizures
Efficacy
Tolerance
Adverse effects
Prescribing
Population
Data collection
Convulsions
Acetic acid
Antiepileptic drugs
Anticonvulsants
Prevalence

Journal Title

Acta Neurologica Scandinavica

Volume

143

Issue

3

Begin page

256

End page

260

Full item page

URI

https://rwt.dspace-express.com/handle/20.500.12687/303

DOI

https://doi.org/10.1111/ane.13368

Abstract

Background: A quarter of people with intellectual disability (ID) have epilepsy, compared to approximately one in a hundred across the general population. Evidence for the safe and effective prescribing of antiepileptic drugs (AEDs) for those with ID is, however, limited. Aims of study: This study seeks to strengthen the research evidence around Eslicarbazepine Acetate (ESL), a new AED, by comparing response of individuals with ID to those from the general population who do not have ID. Methods: A single data set was created through retrospective data collection from English and Welsh NHS Trusts. The UK-based Epilepsy Database Research Register (Ep-ID) data collection and analysis method were used. Results: Data were collected for 93 people (36 ID and 57 'no ID'). Seizure improvement of '>50%' was higher at 12 months for 'no ID' participants (56%), compared to ID participants (35%). Retention rates were slightly higher for those with ID (56% compared to 53%). Neither difference was significant. Conclusions: Tolerance and Efficacy for ID and 'no ID' people in our data set were similar. Seizure improvement and retention rates were slightly lower than that found in other European data sets, but findings strengthen the evidence for the use of ESL in the ID population.

Citation

Allard J, Lawthom C, Henley W, Mclean B, Hudson S, Tittensor P, Rajakulendran S, Ellawela S, Pace A, Shankar R. Eslicarbazepine acetate response in intellectual disability population versus general population. Acta Neurol Scand. 2020 Nov 1. doi: 10.1111/ane.13368. Epub ahead of print. PMID: 33131083.